Option Care Health, Inc. (OPCH) Stock Price & How to Invest

Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). It runs a nationwide network of pharmacies and nursing infrastructure, partners with drug manufacturers for distribution, and contracts with payers and health systems, making it the largest standalone player in a fragmented home-infusion market where the top few providers hold roughly a third of share.

The investment picture in 2026 is one of a defensive, cash-generative business working through a soft patch. Revenue is running around $5.7 billion but growing only about 1 percent as acute chronic-inflammatory-drug (CID) portfolio headwinds, including Stelara and biosimilar census resets, drag on the top line. Management has kept its adjusted EBITDA and adjusted EPS guidance intact, and the stock trades at a below-market earnings multiple, so the debate centers on whether the current drug-mix pressure is transitory or a sign of structural reimbursement and competitive risk in a business with thin margins on high drug pass-through revenue.

The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Because infusion revenue carries large drug pass-through costs, gross margins are thin and sensitive to reimbursement changes, payer contract terms, and manufacturer distribution economics. Competition from CVS Coram, Optum-affiliated Naven Health, and hospital-owned programs pressures pricing and referral flow. Broader policy risk around drug pricing, Medicare and Medicaid rates, and specialty-pharmacy reimbursement could compress economics. Management framed the census reset as a one-time 2026 event with no 2027 carryover, but if chronic declines persist, growth and the profit guidance could come under renewed pressure.

12 analysts publish price targets on OPCH, averaging $28.58 against a $23.64 price as of September 2026, or +20.9%. The published targets run from $23.00 to $39.00, a moderate spread, and the ratings split 8 buy, 5 hold, 0 sell. Over the last six months there have been 0 raises and 7 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full OPCH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Option Care Health, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Acute infusion demand and hospital partnerships. Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. The most optimistic published target, $39.00, assumes this works close to its best case.

The case against. The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. The most pessimistic target, $23.00, is roughly what OPCH is worth if this bites instead.

Read the full bull and bear case on OPCH, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Option Care Health, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$5.7B
• FY2026 revenue guidance: ~$5.68B to $5.78B
• Adjusted EBITDA (FY2026 guide): ~$480M to $505M
• Adjusted EPS (FY2026 guide): ~$1.82 to $1.92
• Market cap: ~$3.4B
• P/E (trailing / forward): ~17x / ~12x

OPCH trades around the low $20s with a market cap near $3.4 billion, a forward P/E in the low teens that sits well below the broader market and many healthcare-services peers. The discount reflects the flat 2026 revenue outlook and drug-mix headwinds rather than a distressed balance sheet, and trailing free cash flow near $170 million underpins the profile.

Other names that sit close to OPCH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get OPCH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so OPCH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where OPCH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Option Care Health is a scaled, profitable infusion-services operator whose near-term revenue is throttled by chronic-drug transitions even as management holds its profit and cash-flow targets.

Whether OPCH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OPCH a buy or a sell?, and where the stock could go from here in the OPCH stock forecast.

For income investors, whether OPCH pays a dividend and how the payout looks is covered in does OPCH pay a dividend? And to weigh OPCH against a peer, read the full side-by-side comparisons: OPCH vs CVS and OPCH vs UNH.